• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Inotiv Provides Notice Regarding Cybersecurity Incident

    2/13/26 4:30:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NOTV alert in real time by email

    WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025.

    As previously described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 18, 2025 and its subsequent SEC filings, Inotiv experienced a cybersecurity incident in early August 2025. While Inotiv currently has no indication that personal information has been misused, it has provided notice via mail and email, and via this release and an accompanying posting on its website, to inform individuals whose personal information was potentially involved. This notification provides details of the incident and Inotiv's response, the resources it is making available to individuals whose personal information has been identified as potentially involved, and additional steps individuals can take if they believe their personal information was potentially involved.

    On August 5, 2025, Inotiv detected unusual activity on certain of its systems and promptly initiated an investigation. On August 8, 2025, Inotiv determined that this unusual activity was due to unauthorized actions by a threat actor. Inotiv's investigation determined that between approximately August 5-8, 2025, a threat actor gained unauthorized access to Inotiv's systems and may have acquired certain data.

    Upon learning of the potential data acquisition, Inotiv took prompt action to identify and review the data and identify individuals whose personal information may have been involved. Inotiv subsequently determined that certain data may have been acquired by the threat actor during this incident, including personal information.

    Inotiv maintains certain data related to current and former employees of Inotiv and their family members, as well as certain data related to other individuals who have interacted with Inotiv or companies it has acquired. Inotiv's review determined that the personal information potentially involved included names, Social Security numbers, tax identification numbers, driver's license numbers, other government-issued identification numbers or details, dates of birth, financial account information, payment card information, health insurance information, medical information, biometric data, passport information, digital signatures, and contact information, among other types of information.

    Upon detecting the unusual activity, Inotiv promptly took steps to contain it and launched an investigation with the support of external cybersecurity specialists. Inotiv also notified regulators and U.S. law enforcement. Notification was not delayed as a result of a law enforcement investigation.

    Inotiv has notified individuals whose personal information was potentially involved via mail and email where such contact information was available and has offered complimentary credit monitoring to these individuals. Inotiv is further posting substitute notice on its website and issuing this release for the limited number of individuals whose information was potentially involved but for whom Inotiv could not locate valid contact information.

    Inotiv recommends that individuals remain vigilant for incidents of fraud and identity theft, including by regularly reviewing and monitoring their credit history and credit reports to detect any errors and guard against any unauthorized transactions or activity. Inotiv also recommends that individuals closely monitor their account statements and notify their financial institution if they suspect any unauthorized activity.

    Please be assured that Inotiv has taken steps to address the incident and to further enhance its security measures to protect individuals' data. If you have any questions about this notice or the incident and believe your information may have been potentially involved, please contact (833) 918-5956 (U.S. residents, toll-free) or (214) 393-3323 (individuals outside the U.S.) Monday through Friday, from 8 am to 8 pm Central Time (excluding major U.S. holidays) or [email protected]. Please be prepared to provide engagement number B158971.

    About Inotiv

    Inotiv, Inc. is a leading contract research organization dedicated to providing non-clinical and analytical drug discovery and development services and research models and related products and services. The Company's products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.

    This release contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include statements regarding the Company's assessment of the cybersecurity incident, ongoing or potential impacts, and efforts of the Company related to the incident. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: the results of further analyses of the scope and details of the data that the threat actor accessed; release by the threat actor of any of the Company's data, including third party data held by the Company, or the use of any such data for any fraudulent purposes; potential adverse impact of the incident on the Company's results of operations, including revenue, operating income and cash flows from operations, and on its financial condition, including liquidity; diversion of management's attention from operations of the Company to addressing the cybersecurity incident; potential litigation related to the cybersecurity incident; potential adverse effects on relationships with customers, suppliers and other third parties as a result of the cybersecurity incident; reputational risk related to the cybersecurity incident; regulatory scrutiny of the cybersecurity incident; and various other risks, including those detailed in the Company's filings with the SEC.

    Company Contact Investor Relations
    Inotiv, Inc. LifeSci Advisors
    Beth A. Taylor, Chief Financial Officer Steve Halper
    (765) 497-8381 (646) 876-6455
    [email protected] [email protected]





    Primary Logo

    Get the next $NOTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NOTV

    DatePrice TargetRatingAnalyst
    5/14/2024$11.50 → $3.75Buy → Hold
    Jefferies
    2/9/2024$3.00 → $11.50Hold → Buy
    Jefferies
    7/20/2023$9.00Overweight
    Wells Fargo
    1/19/2023$10.00 → $8.00Buy → Hold
    Jefferies
    1/11/2023$4.00 → $10.00Hold → Buy
    Lake Street
    11/18/2022$60.00 → $7.00Buy → Hold
    Lake Street
    10/4/2022$27.00Buy
    Jefferies
    1/31/2022$60.00Buy
    Lake Street
    More analyst ratings

    $NOTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Leasure Robert Jr. sold $57,034 worth of shares (113,297 units at $0.50), decreasing direct ownership by 8% to 1,273,025 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    2/3/26 4:14:39 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by EVP, General Counsel & Sec'y Castetter Andrea

    4 - Inotiv, Inc. (0000720154) (Issuer)

    1/16/26 4:07:23 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Inotiv Inc.

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/2/25 4:41:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Landman David bought $99,998 worth of shares (23,529 units at $4.25), increasing direct ownership by 15% to 176,851 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/23/24 9:47:13 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Operating Officer Beattie John Gregory bought $142,500 worth of shares (30,000 units at $4.75), increasing direct ownership by 23% to 161,761 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/12/24 6:46:46 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Brown Nigel bought $31,950 worth of shares (7,500 units at $4.26), increasing direct ownership by 13% to 65,537 units (SEC Form 4)

    4 - Inotiv, Inc. (0000720154) (Issuer)

    12/10/24 4:13:30 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Inotiv downgraded by Jefferies with a new price target

    Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously

    5/14/24 8:01:45 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv upgraded by Jefferies with a new price target

    Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously

    2/9/24 6:17:55 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Wells Fargo initiated coverage on Inotiv with a new price target

    Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00

    7/20/23 7:55:03 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inotiv Provides Notice Regarding Cybersecurity Incident

    WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 18, 2025 and its subsequent SEC filings, Inotiv experienced a cybersecurity incident in early August 2025. While Inotiv currently has no indication that perso

    2/13/26 4:30:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

    –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD)  Three Months Ende

    2/9/26 7:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

    WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-445-7795 (Domestic)1-785-424-1699 (International)INOTIV (Co

    2/4/26 6:30:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    SEC Filings

    View All

    SEC Form 10-Q filed by Inotiv Inc.

    10-Q - Inotiv, Inc. (0000720154) (Filer)

    2/9/26 4:23:58 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Inotiv, Inc. (0000720154) (Filer)

    2/9/26 7:30:44 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form 10-K/A filed by Inotiv Inc.

    10-K/A - Inotiv, Inc. (0000720154) (Filer)

    1/28/26 4:29:48 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Leadership Updates

    Live Leadership Updates

    View All

    Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    3/7/24 4:05:00 PM ET
    $BDN
    $NOTV
    $OLED
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. Announces Changes to its Board Composition

    WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic

    10/16/23 8:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    4/3/24 10:47:10 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    10/6/22 12:24:15 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

    9/20/22 9:00:08 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NOTV
    Financials

    Live finance-specific insights

    View All

    Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update

    –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD)  Three Months Ende

    2/9/26 7:00:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026

    WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-445-7795 (Domestic)1-785-424-1699 (International)INOTIV (Co

    2/4/26 6:30:00 AM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

    –  Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million–  Fiscal 2025 revenue increased 4.5% to $513.0 million–  Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million–  Fiscal 2025 operating loss decreased 64.2% to $30.9 million–  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2025") ended September 30, 2025, and twelve mo

    12/3/25 4:05:00 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care